-
公开(公告)号:US10034959B2
公开(公告)日:2018-07-31
申请号:US15156108
申请日:2016-05-16
IPC分类号: A61K31/695 , A61K9/12 , A61P17/02 , A61P17/16 , A61L26/00
CPC分类号: A61L26/0052 , A61K9/12 , A61K31/695 , A61K31/80 , A61L26/0014 , A61L26/0019 , A61L26/0076 , A61L26/0085 , A61L2300/404 , A61L2300/802 , A61P17/00 , A61P17/02 , Y02A50/473 , A61K2300/00
摘要: Provided, among other things, is a method of treating skin and soft tissue wounds, ulcers, burns, various types of dermatoses, inflammatory conditions of the mucosa, and the like comprising: periodically applying to the wound, inflammatory condition of mucosal tissues, or dermatoses, over a course of days an effective amount of water based formulation (comprising: 0.5 to 5 wt % of an emollient comprising silicone oil, 2 to 10 wt % of fatty acid, humectant(s), emulsifying agent(s), and polymer(s)), wherein the formulation is formulated as a spray, cream, lotion, milk or foam-former.
-
公开(公告)号:US20180133359A1
公开(公告)日:2018-05-17
申请号:US15570276
申请日:2016-04-28
CPC分类号: A61L15/46 , A61L15/28 , A61L15/44 , A61L15/62 , A61L2300/404 , A61L2300/802 , A61L2400/12 , C08L5/04
摘要: Antibacterial nanofibres and methods for their preparation are described. Antibacterial nanofibres include as-spun alginate nanofibres treated with silver to generate silver-alginate nanofibres. Antibacterial nanofibres provided are useful components of wound dressings, wherein the wound dressings optionally further comprise malodor absorbing agents such as cyclodextrins.
-
公开(公告)号:US20180110903A1
公开(公告)日:2018-04-26
申请号:US15850010
申请日:2017-12-21
申请人: Surmodics, Inc.
发明人: Joram Slager , Toni M. Heyer , David E. Babcock
CPC分类号: A61L29/085 , A61K9/5031 , A61K31/337 , A61K31/713 , A61K47/34 , A61L29/14 , A61L29/16 , A61L2300/258 , A61L2300/416 , A61L2300/606 , A61L2300/608 , A61L2300/62 , A61L2300/802 , A61L2420/06 , A61L2420/08 , A61M25/10 , A61M2025/105 , C12N15/113 , C12N2310/14 , C12N2320/32 , C08L39/06 , C08L33/26
摘要: Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.
-
公开(公告)号:US09931430B2
公开(公告)日:2018-04-03
申请号:US15016534
申请日:2016-02-05
申请人: Heraeus Medical Gmbh
发明人: Sebastian Vogt
IPC分类号: A61L24/06 , A61L24/04 , A61L27/54 , A61L24/00 , A61K31/7048
CPC分类号: A61L24/043 , A61K31/7048 , A61L24/0015 , A61L24/0073 , A61L24/06 , A61L27/54 , A61L2300/406 , A61L2300/802 , A61L2430/02 , A61L2430/38
摘要: The invention describes a bone cement with antimycotic efficacy based on organic polymers, such as polymethylmethacrylate. The bone cement comprises an antimycotic agent, in particular amphotericin B, that is released from the polymerized bone cement in the presence of water or aqueous media, such as body fluids. According to one alternative, the antimycotic agent is present in particulate form and is encapsulated, at least in part, by a mixture of at least one 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid. In addition, a method for the production of a mixture comprising an antimycotic agent, such as amphotericin B particles, and 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid is proposed. Preferably, the antimycotic agent is encapsulated, at least partially, by 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid.
-
公开(公告)号:US09861727B2
公开(公告)日:2018-01-09
申请号:US14609270
申请日:2015-01-29
申请人: SurModics, Inc.
发明人: Joram Slager , Toni M. Heyer , David E. Babcock
IPC分类号: A61L29/08 , A61L29/16 , A61L29/14 , A61K31/337 , A61K9/50
CPC分类号: A61L29/085 , A61K9/5031 , A61K31/337 , A61K31/713 , A61K47/34 , A61L29/14 , A61L29/16 , A61L2300/258 , A61L2300/416 , A61L2300/606 , A61L2300/608 , A61L2300/62 , A61L2300/802 , A61L2420/06 , A61L2420/08 , A61M25/10 , A61M2025/105 , C12N15/113 , C12N2310/14 , C12N2320/32 , C08L39/06 , C08L33/26
摘要: Embodiments of the invention include drug delivery coatings and devices including the same. In an embodiment, the invention includes a drug delivery coating including a polymeric layer. The polymeric layer can include a hydrophilic outer surface. The coating can also include a matrix contacting the hydrophilic outer surface. The matrix can include a particulate hydrophobic therapeutic agent and a cationic agent. The polymeric layer can further include a hydrophilic polymer having pendent photoreactive groups and a photo-crosslinker including two aryl ketone functionalities. Other embodiments are also included herein.
-
6.
公开(公告)号:US20170368235A1
公开(公告)日:2017-12-28
申请号:US15694921
申请日:2017-09-04
申请人: Thomas Q. Dinh
发明人: Thomas Q. Dinh
CPC分类号: A61L29/16 , A61L29/085 , A61L2300/416 , A61L2300/436 , A61L2300/45 , A61L2300/606 , A61L2300/802 , A61L2420/06 , A61M2025/105 , C08L33/08 , C08L75/04
摘要: A method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising a coating layer of two hydrophobic drugs applied to an exterior surface of a device or a substrate wherein the first pharmaceutically active agent is selected from a group consisting of mTor inhibitors and the second pharmaceutically active agent is selected from a group of consisting of NF-kβ inhibitors. Further a method for treating proliferative diseases by delivering a combination of at least two pharmaceutically active agents to a diseased area or tissue comprising: a coating layer of two hydrophobic drugs applied to an exterior surface of a medical device or substrate and a polymer blend carrier for the pharmaceutically active agents.
-
公开(公告)号:US09849218B2
公开(公告)日:2017-12-26
申请号:US15295445
申请日:2016-10-17
发明人: Jeffrey L. Scifert
IPC分类号: A61K9/16 , A61K38/18 , A61L27/54 , A61K9/00 , A61K9/12 , A61L27/14 , A61L27/56 , A61L27/22 , A61L27/40
CPC分类号: A61L27/54 , A61K9/0024 , A61K9/122 , A61K9/1629 , A61K38/1875 , A61L27/14 , A61L27/227 , A61L27/40 , A61L27/56 , A61L2300/414 , A61L2300/802 , A61L2430/02
摘要: An improved osteogenic composition is provided. The composition comprises a foam that contains polymer beads having one or more growth factors such as bone morphogenic protein. Through use of this composition, bone, collagen and/or other tissue growth may be facilitated.
-
公开(公告)号:US09833539B2
公开(公告)日:2017-12-05
申请号:US15100222
申请日:2013-12-28
发明人: Hong Xu , Bo Chi , Rui Wang , Xiaohai Feng , Sha Li , Jinfeng Liang , Pingkai Ouyang
IPC分类号: C08G69/40 , A61L26/00 , C08J3/075 , A61L15/32 , A61L15/60 , C08G69/10 , C08G69/48 , C12P13/08
CPC分类号: A61L26/0019 , A61L15/32 , A61L15/60 , A61L26/0047 , A61L26/008 , A61L26/009 , A61L2300/252 , A61L2300/802 , A61L2430/34 , C08G69/10 , C08G69/40 , C08G69/48 , C08J3/075 , C08J2377/04 , C08J2389/00 , C12P13/08 , C08L77/04
摘要: The present invention discloses a ε-polylysine hydrogel and the preparation method and application of the as-described ε-polylysine hydrogel. The polylysine hydrogel is non-toxic to a recipient, and has biodegradability and biocompatibility. The wound tissue healing material prepared by the present invention can be used in wound tissue adhesion in an efficient, stable, safe manner.
-
公开(公告)号:US09757351B2
公开(公告)日:2017-09-12
申请号:US15067734
申请日:2016-03-11
申请人: Lutonix, Inc.
发明人: Lixiao Wang
IPC分类号: A61K31/337 , A61K31/436 , A61L29/16 , A61L31/16 , A61L29/08 , A61L31/08 , A61F2/82 , A61M25/10
CPC分类号: A61K31/337 , A61F2/82 , A61F2250/0067 , A61K31/436 , A61L29/08 , A61L29/16 , A61L31/08 , A61L31/16 , A61L2300/22 , A61L2300/416 , A61L2300/602 , A61L2300/802 , A61M25/10 , A61M25/1029 , A61M25/104 , A61M2025/1031 , A61M2025/105 , A61K2300/00
摘要: The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.
-
公开(公告)号:US20170239358A1
公开(公告)日:2017-08-24
申请号:US15277928
申请日:2016-09-27
发明人: David M. Gravett , George Y. Daniloff , Pingren He
IPC分类号: A61K47/36 , A61K47/34 , A61L24/00 , C08B37/08 , A61L24/04 , A61L24/08 , A61K9/06 , A61K31/58
CPC分类号: A61K47/36 , A61K9/06 , A61K31/58 , A61K31/728 , A61K31/765 , A61K45/06 , A61K47/34 , A61L24/0015 , A61L24/0042 , A61L24/043 , A61L24/046 , A61L24/08 , A61L26/0019 , A61L26/0023 , A61L26/008 , A61L27/18 , A61L27/20 , A61L27/52 , A61L27/54 , A61L31/042 , A61L31/06 , A61L31/145 , A61L31/16 , A61L2300/222 , A61L2300/604 , A61L2300/802 , A61L2400/06 , C08B37/0072 , C08L5/08 , C08L71/02
摘要: The present application provides rapid-gelling, sprayable hyaluronic-acid based compositions, kits, related methods, precursor formulations, and uses thereof.
-
-
-
-
-
-
-
-
-